ARTICLE | Clinical News
Second Vertex drug caught in CF standoff
August 10, 2018 6:38 PM UTC
NICE's suspension of its review of Symkevi tezacaftor/ivacaftor on Aug. 9 marks the latest delay of access in England and Wales to cystic fibrosis drugs from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).
NICE suspended its review after the company did not provide an evidence submission, according to the committee's website. It also canceled plans to discuss Symkevi's appraisal at a Nov. 8 meeting...
BCIQ Company Profiles
BCIQ Target Profiles